装入脂质纳米颗粒的维生素D在INS-1E细胞中表现出胰岛素otropic作用
Cecília Cristelo1, Ana Filipa Sá2, Marlene Lúcio3
1i3S, Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal; Centro de Engenharia Biológica, Universidade do Minho, Campus de Gualtar, Braga, Portugal; ICBAS, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.
概括
纳米结构脂质载体 (NLCs) 提供了改善的维生素D3 (VitD3) 输送,增强生物可用性和持续释放. NLCs对治疗应用有希望,包括改善依赖葡萄糖的胰岛素分泌.
科学领域:
- 纳米技术 纳米技术
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 维生素D缺乏症很普遍,目前的维生素D3 (VitD3) 配方在生物可用性和安全性方面存在限制.
- 基于纳米粒子的传递系统正在探索以克服这些挑战.
研究的目的:
- 为了改善VitD3传递,研究聚L-乳酸-co-glycolide) 纳米粒子 (PLGA NPs),固体脂质纳米粒子 (SLNs) 和纳米结构脂质载体 (NLCs).
- 评估 VitD3 装载纳米粒子的特性,稳定性和生物效应.
主要方法:
- 准备和描述PLGA NP,SLN和NLC.
- 评估VitD3关联效率 (AE) 和释放概况.
- 对INS-1E细胞的纳米粒子稳定性和细胞毒性的评估.
- 测量依赖葡萄糖的胰岛素分泌物,以应对VitD3治疗.
主要成果:
- PLGA NPs显示出快速的VitD3释放,而SLNs则显示出爆发释放.
- 在NLC中,VitD3负载高 (99% AE) 和持续释放近一个月.
- NLCs对INS-1E细胞稳定且非细胞毒性.
- 无论是自由的还是载有NLC的VitD3,都将依赖葡萄糖的胰岛素分泌量增加了约30%.
结论:
- NLCs代表了VitD3的有希望的输送系统,提供增强的稳定性,持续释放和改善的治疗潜力.
- 这项研究阐明了VitD3对胰腺β细胞功能的影响,并强调了NLCs作为一种可行的配方策略.
相关概念视频
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Insulin: Dosing Regimen and Adverse Effects
169
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
169
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K


